Terms: = Leukemia AND LMO2, RBTN2, 4005, ENSG00000135363, P25791, TTG2, RBTNL1, RHOM2
219 results:
1. A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID.
Cesana D; Cicalese MP; Calabria A; Merli P; Caruso R; Volpin M; Rudilosso L; Migliavacca M; Barzaghi F; Fossati C; Gazzo F; Pizzi S; Ciolfi A; Bruselles A; Tucci F; Spinozzi G; Pais G; Benedicenti F; Barcella M; Merelli I; Gallina P; Giannelli S; Dionisio F; Scala S; Casiraghi M; Strocchio L; Vinti L; Pacillo L; Draghi E; Cesana M; Riccardo S; Colantuono C; Six E; Cavazzana M; Carlucci F; Schmidt M; Cancrini C; Ciceri F; Vago L; Cacchiarelli D; Gentner B; Naldini L; Tartaglia M; Montini E; Locatelli F; Aiuti A
Nat Commun; 2024 Apr; 15(1):3662. PubMed ID: 38688902
[TBL] [Abstract] [Full Text] [Related]
2. The role of quiescent thymic progenitors in TAL/lmo2-induced T-ALL chemotolerance.
O'Connor KW; Kishimoto K; Kuzma IO; Wagner KP; Selway JS; Roderick JE; Karna KK; Gallagher KM; Hu K; Liu H; Li R; Brehm MA; Zhu LJ; Curtis DJ; Tremblay CS; Kelliher MA
Leukemia; 2024 May; 38(5):951-962. PubMed ID: 38553571
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic utility of lmo2 immunohistochemistry in distinguishing T-lymphoblastic leukemia/lymphoma from thymoma.
Bansal D; Pasricha S; Gupta G; Sharma A; Durga G; Kamboj M; Mehta A
Indian J Pathol Microbiol; 2024; 67(1):141-144. PubMed ID: 38358204
[TBL] [Abstract] [Full Text] [Related]
4. ZNF683 marks a CD8
Parry EM; Lemvigh CK; Deng S; Dangle N; Ruthen N; Knisbacher BA; Broséus J; Hergalant S; Guièze R; Li S; Zhang W; Johnson C; Long JM; Yin S; Werner L; Anandappa A; Purroy N; Gohil S; Oliveira G; Bachireddy P; Shukla SA; Huang T; Khoury JD; Thakral B; Dickinson M; Tam C; Livak KJ; Getz G; Neuberg D; Feugier P; Kharchenko P; Wierda W; Olsen LR; Jain N; Wu CJ
Cancer Cell; 2023 Oct; 41(10):1803-1816.e8. PubMed ID: 37738974
[TBL] [Abstract] [Full Text] [Related]
5. lmo2 promotes the development of AML through interaction with transcription co-regulator LDB1.
Lu L; Wang J; Fang F; Guo A; Jiang S; Tao Y; Zhang Y; Li Y; Zhang K; Zhang Z; Zhuo R; Chu X; Li X; Tian Y; Ma L; Sang X; Chen Y; Yu J; Yang Y; Cao H; Gao J; Lu J; Hu S; Pan J; He H
Cell Death Dis; 2023 Aug; 14(8):518. PubMed ID: 37573405
[TBL] [Abstract] [Full Text] [Related]
6. Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.
Quintanilla-Martinez L; Laurent C; Soma L; Ng SB; Climent F; Ondrejka SL; Zamo A; Wotherspoon A; de Leval L; Dirnhofer S; Leoncini L
Virchows Arch; 2023 Sep; 483(3):281-298. PubMed ID: 37555980
[TBL] [Abstract] [Full Text] [Related]
7. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.
Tremblay CS; Saw J; Boyle JA; Haigh K; Litalien V; McCalmont H; Evans K; Lock RB; Jane SM; Haigh JJ; Curtis DJ
Blood; 2023 Jul; 142(3):274-289. PubMed ID: 36989489
[TBL] [Abstract] [Full Text] [Related]
8. Overexpression of lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition.
Abdulla HD; Alserihi R; Flensburg C; Abeysekera W; Luo MX; Gray DHD; Liu X; Smyth GK; Alexander WS; Majewski IJ; McCormack MP
J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36920307
[TBL] [Abstract] [Full Text] [Related]
9. PAK5 is a potential target in myelodysplastic syndrome through interacting with lmo2 and GATA1.
Pan X; Liu D; Ying M; Zheng G; Fan C; Pan F; Ke Q
Cell Mol Biol (Noisy-le-grand); 2022 Sep; 68(9):77-85. PubMed ID: 36905268
[TBL] [Abstract] [Full Text] [Related]
10. SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid leukemia.
Chambers C; Cermakova K; Chan YS; Kurtz K; Wohlan K; Lewis AH; Wang C; Pham A; Dejmek M; Sala M; Loeza Cabrera M; Aguilar R; Nencka R; Lacorazza HD; Rau RE; Hodges HC
Cancer Res; 2023 Apr; 83(7):983-996. PubMed ID: 36662812
[TBL] [Abstract] [Full Text] [Related]
11. LYL1 facilitates AETFC assembly and gene activation by recruiting CARM1 in t(8;21) AML.
Chen Q; Cevher MA; Jiang Q; Wang S; Sun X; Roeder RG; Chen M
Proc Natl Acad Sci U S A; 2022 Oct; 119(42):e2213718119. PubMed ID: 36215477
[TBL] [Abstract] [Full Text] [Related]
12. A comprehensive analysis of lmo2 pathogenic regulatory profile during T-lineage development and leukemic transformation.
Wang W; Meng Y; Chen Y; Yu Y; Wang H; Yang S; Sun W
Oncogene; 2022 Aug; 41(34):4079-4090. PubMed ID: 35851847
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia.
Kumari S; Ali MS; Singh J; Arora M; Verma D; Pandey AK; Benjamin M; Bakhshi S; Palanichamy JK; Sharma A; Singh I; Tanwar P; Singh AR; Pushpam D; Qamar I; Chopra A
Hematol Oncol; 2022 Oct; 40(4):577-587. PubMed ID: 35644022
[TBL] [Abstract] [Full Text] [Related]
14. Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases.
Dai YT; Zhang F; Fang H; Li JF; Lu G; Jiang L; Chen B; Mao DD; Liu YF; Wang J; Peng LJ; Feng C; Chen HF; Mu JX; Zhang QL; Wang H; Ariffin H; Moy TA; Wang JH; Lou YJ; Chen SN; Wang Q; Liu H; Shan Z; Matsumura I; Miyazaki Y; Yasuda T; Dou LP; Yan XJ; Yan JS; Yeoh AE; Wu DP; Kiyoi H; Hayakawa F; Jin J; Wang SY; Sun XJ; Mi JQ; Chen Z; Huang JY; Chen SJ
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2120787119. PubMed ID: 35385357
[TBL] [Abstract] [Full Text] [Related]
15. lmo2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage.
Latchmansingh KA; Wang X; Verdun RE; Marques-Piubelli ML; Vega F; You MJ; Chapman J; Lossos IS
Mod Pathol; 2022 Sep; 35(9):1220-1226. PubMed ID: 35322192
[TBL] [Abstract] [Full Text] [Related]
16. Fli1
Matrone G; Xia B; Chen K; Denvir MA; Baker AH; Cooke JP
Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34330825
[TBL] [Abstract] [Full Text] [Related]
17. Disruption of a GATA2-TAL1-ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells.
Thoms JAI; Truong P; Subramanian S; Knezevic K; Harvey G; Huang Y; Seneviratne JA; Carter DR; Joshi S; Skhinas J; Chacon D; Shah A; de Jong I; Beck D; Göttgens B; Larsson J; Wong JWH; Zanini F; Pimanda JE
Blood; 2021 Oct; 138(16):1441-1455. PubMed ID: 34075404
[TBL] [Abstract] [Full Text] [Related]
18. Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias.
Lestringant V; Duployez N; Penther D; Luquet I; Derrieux C; Lutun A; Preudhomme C; West M; Ouled-Haddou H; Devoldere C; Marolleau JP; Garçon L; Jedraszak G; Ferret Y
Genes Chromosomes Cancer; 2021 Oct; 60(10):657-667. PubMed ID: 33982372
[TBL] [Abstract] [Full Text] [Related]
19. Competitive SPR using an intracellular anti-lmo2 antibody identifies novel lmo2-interacting compounds.
Canning P; Bataille C; Bery N; Milhas S; Hayes A; Raynaud F; Miller A; Rabbitts T
J Immunol Methods; 2021 Jul; 494():113051. PubMed ID: 33794223
[TBL] [Abstract] [Full Text] [Related]
20. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.
Takao S; Forbes L; Uni M; Cheng S; Pineda JMB; Tarumoto Y; Cifani P; Minuesa G; Chen C; Kharas MG; Bradley RK; Vakoc CR; Koche RP; Kentsis A
Elife; 2021 Feb; 10():. PubMed ID: 33527899
[TBL] [Abstract] [Full Text] [Related]
[Next]
